| 1.13 -0.03 (-2.59%) | 01-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.69  |
1-year : | 1.92 |
| Resists | First : | 1.44 |
Second : | 1.64 |
| Pivot price | 1.33 |
|||
| Supports | First : | 1.12 |
Second : | 0.93 |
| MAs | MA(5) : | 1.2 |
MA(20) : | 1.39 |
| MA(100) : | 1.53 |
MA(250) : | 2.18 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 8.6 |
D(3) : | 9.3  |
| RSI | RSI(14): 26 |
|||
| 52-week | High : | 4.9 | Low : | 1.12 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MXCT ] has closed above bottom band by 14.9%. Bollinger Bands are 74.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.19 - 1.19 | 1.19 - 1.2 |
| Low: | 1.11 - 1.11 | 1.11 - 1.12 |
| Close: | 1.14 - 1.15 | 1.15 - 1.16 |
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
Mon, 12 Jan 2026
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results - The Globe and Mail
Sat, 10 Jan 2026
MaxCyte (NASDAQ:MXCT) Stock Rating Lowered by Wall Street Zen - MarketBeat
Thu, 08 Jan 2026
MaxCyte (NASDAQ:MXCT) Shares Up 0.7% - Time to Buy? - MarketBeat
Wed, 12 Nov 2025
MaxCyte (NASDAQ: MXCT) begins CFO succession search, transition in first half 2026 - Stock Titan
Tue, 23 Sep 2025
Rockville's MaxCyte slashes workforce by 34% amid revenue struggles - The Business Journals
Mon, 22 Sep 2025
34% Workforce Reduction: MaxCyte's $13.6M Cost-Cutting Plan Aims to Accelerate Path to Profitability - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 107 (M) |
| Shares Float | 97 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 75 (%) |
| Shares Short | 2,380 (K) |
| Shares Short P.Month | 2,820 (K) |
| EPS | -0.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.69 |
| Profit Margin | -132.6 % |
| Operating Margin | -162.5 % |
| Return on Assets (ttm) | -13.7 % |
| Return on Equity (ttm) | -23.2 % |
| Qtrly Rev. Growth | -16.4 % |
| Gross Profit (p.s.) | 0.25 |
| Sales Per Share | 0.32 |
| EBITDA (p.s.) | -0.44 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -40 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -2.69 |
| PEG Ratio | 0 |
| Price to Book value | 0.68 |
| Price to Sales | 3.57 |
| Price to Cash Flow | -3.12 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|